Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: Implications for antiretroviral therapy in HBV and HIV co-infected south African patients

被引:44
作者
Selabe, S. Gloria
Lukhwareni, Azwidowi
Song, Ernest
Leeuw, Yeegan G. M.
Burnett, Rosemary J.
Mphahlele, M. Jeffrey
机构
[1] Univ Limpopo, Dept Virol, HIV & Hepatitis Res Unit, Pretoria, South Africa
[2] Johannesburg Hosp, Hepatol Div, Dept Med, Johannesburg, South Africa
[3] Univ Witwatersrand, Johannesburg, South Africa
[4] Margarita Hlth Ctr, Pretoria, South Africa
关键词
lamivudine-resistant HBV strains; hepatitis B virus; human immunodeficiency virus; HBV-HIV coinfection; sub-Saharan Africa;
D O I
10.1002/jmv.20974
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
This was an exploratory study to investigate larnivudine-resistant hepatitis 13 virus (HBV) strains in selected lamivudine-naive HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients. Thirty-five lamivudine-naive HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HlV co-infected patients. The latter group was further sub-divided into 13 occult HBV (HBsAg-negative) and 7 overt HBV (HBsAg-positive) patients. HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL). Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme. HBV viral load was performed with Amplicor HBV Monitor((R)) test v2.0 (Roche Diagnostics, Penzberg, Germany). HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients. To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-naive HBV-HIV co-infected patients. The HBV viral loads for mono-infected and co-infected patients ranged from 3.32 x 10(2) to 3.82 x 10(7) and < 200 to 4.40 x 10(3) copies/ml, respectively. It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.
引用
收藏
页码:1650 / 1654
页数:5
相关论文
共 50 条
  • [21] Longer Duration of HBV-Active Antiretroviral Therapy is Linked to Favorable Virological Outcome in HIV-HBV Co-infected Patients
    Lee, Tsan
    Nunez, Marina
    HIV CLINICAL TRIALS, 2009, 10 (03): : 153 - 159
  • [22] Epidemiology of HBV infection in a cohort of Ugandan HIV-infected patients and rate and pattern of lamivudine-resistant HBV infection in patients receiving antiretroviral therapy
    Calisti, Giorgio
    Muhindo, Rose
    Boum, Yap, II
    Wilson, Laurence A.
    Foster, Geraldine M.
    Geretti, Anna Maria
    Bhagani, Sanjay
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2015, 109 (11) : 723 - 729
  • [23] Hepatitis B Virus (HBV) X Gene Diversity and Evidence of Recombination in HBV/HIV Co-Infected Persons
    Martin, Christina M.
    Welge, Jeffrey A.
    Blackard, Jason T.
    JOURNAL OF MEDICAL VIROLOGY, 2011, 83 (07) : 1142 - 1150
  • [24] Active Co-Infection With HBV and/or HCV in South African HIV Positive Patients Due For Cancer Therapy
    Musyoki, Andrew M.
    Msibi, Thembeni L.
    Motswaledi, Mojakgomo H.
    Selabe, Selokela G.
    Monokoane, Tshweu S.
    Mphahlele, M. Jeffrey
    JOURNAL OF MEDICAL VIROLOGY, 2015, 87 (02) : 213 - 221
  • [25] Molecular Characterization of Hepatitis B Virus Strains Circulating in Belgian Patients Co-Infected With HIV and HBV: Overt and Occult Infection
    Pourkarim, Mahmoud Reza
    Lemey, Philippe
    Amini-Bavil-Olyaee, Samad
    Houspie, Lieselot
    Verbeeck, Jannick
    Rahman, Mustafizur
    Maes, Piet
    Vanwijngaerden, Eric
    Nevens, Frederik
    Van Ranst, Marc
    JOURNAL OF MEDICAL VIROLOGY, 2011, 83 (11) : 1876 - 1884
  • [26] Liver fibrosis in treatment-naive HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared
    Wandeler, Gilles
    Mulenga, Lloyd
    Vinikoor, Michael J.
    Kovari, Helen
    Battegay, Manuel
    Calmy, Alexandra
    Cavassini, Matthias
    Bernasconi, Enos
    Schmid, Patrick
    Bolton-Moore, Carolyn
    Sinkala, Edford
    Chi, Benjamin H.
    Egger, Matthias
    Rauch, Andri
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2016, 51 : 97 - 102
  • [27] Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada
    Rana, Urvi
    Driedger, Matt
    Sereda, Paul
    Pan, Shenyi
    Ding, Erin
    Wong, Alex
    Walmsley, Sharon
    Klein, Marina
    Kelly, Deborah
    Loutfy, Mona
    Thomas, Rejean
    Sanche, Stephen
    Kroch, Abigail
    Machouf, Nima
    Roy-Gagnon, Marie-Helene
    Hogg, Robert
    Cooper, Curtis L.
    BMC INFECTIOUS DISEASES, 2019, 19 (01)
  • [28] Study of liver function tests in HIV-infected patients, with or without co-infection of HBV or HCV
    Hashemy, Seyed Isaac
    Rad, Robabeh Omidian
    Riazi, Zahra
    Hadi, Sadeghian Mohamamd
    CLINICAL BIOCHEMISTRY, 2011, 44 (13) : S126 - S127
  • [29] The Prevalence and Risk Factors of Hepatitis Delta Virus in HIV/HBV Co-Infected Patients in Shiraz, Iran, 2012
    Motamedifar, Mohammad
    Taheri, Mohammad
    Lankarani, Kamran Bagheri
    Gholami, Mina
    Lari, Mahmood Amini
    Faramarzi, Hossein
    Sarvari, Jamal
    IRANIAN JOURNAL OF MEDICAL SCIENCES, 2015, 40 (05) : 448 - 453
  • [30] Long-term observation on hepatitis B surface antigen seroclearance in therapy experienced HIV/HBV co-infected Chinese
    Yang, Rongrong
    Gui, Xien
    Ke, Hengning
    Xiong, Yong
    Gao, Shicheng
    JOURNAL OF VIRAL HEPATITIS, 2020, 27 (02) : 127 - 134